BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Fulcrum Therapeutics Inc

These recent winners still have a long way to run.

2 Soaring Biotech Stocks With More Fuel in the Tank

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says that it is well-capitalized, with cash, cash equivalents, restricted cash, and investments of $222.8 million as of June 30, 2021.

BioCryst Stock Jumps After Pulling Out $200M Equity Raise

RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO ® (berotralstat), we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders.   We are well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021.   Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.

BioCryst Withdraws Public Offering

RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $200 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

The company's first commercial drug launch keeps exceeding expectations.

Why BioCryst Pharmaceuticals Rose 8% on Thursday

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of $50 million, with $28.5 million of net revenue coming from the company's product Orladeyo.

BioCryst Pharma Stock Heads Higher Thursday: Here's Why

Tesla

Exxon Mobil

Affirm

First Solar

Iridium Communications

SolarEdge Technologies

Tractor Supply

With the trading day more than halfway over, the broad markets were pushing higher yet again.

Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More

Eli Lilly

Rigel Pharmaceuticals

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

3 Biotech Stocks That Could Rocket Higher

RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021.

BioCryst to Report Second Quarter 2021 Financial Results on August 5

Sales of HAE drug ORLADEYO in 1Q21 were surprisingly strong at $10.9 million, reflecting the demand for an oral drug for this indication. We expect continued exceptional demand for ORLADEYO in 2Q and the rest of 2021, beating analyst expectations.

BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH). REDEEM-1 will compare the efficacy and safety of BCX9930 monotherapy versus C5 inhibitor in approximately 81 PNH patients.

BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder

RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients. The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline.

BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO— —Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO—

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress from July 10-12, 2021.

ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

There's more than one opportunity for it to do so.

Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?

— Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel — — Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel —

BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health

Bionano Genomics

BioNTech SE

Avid Bioservices

Moderna

VistaGen Therapeutics

22nd Century Group

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

7 A-Rated Biotech Stocks to Buy Now

BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside

Beyond Meat

Meme stocks AMC Entertainment Holdings Inc (NYSE: AMC) and GameStop Corp. (NYSE: GME) are on the move once again this week, fueled by targeted buying campaigns driven by Reddit's WallStreetBets community. On Thursday, Bank of America analyst Jill Carey Hall said AMC and GameStop are flashing sell signals at this point — but there may be two new WallStreetBets stocks to watch in the week ahead.

Forget AMC, GameStop: Analyst Names 2 New Reddit Stocks Traders Should Watch

This commercial-stage drugmaker trades for less than many of its clinical-stage peers.

Is BioCryst a Good Stock to Buy Now?

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

Tonix Pharmaceuticals Hld

Shares of these biotechs have been soaring in the opposite direction of their peers.

2 Biotech Stocks Bucking the Trend Right Now

Investors appear to be increasingly optimistic about the outlook for its drug Orladeyo.

News for BioCryst Pharmaceuticals Stock (BCRX)